CBG vs CBN for Anxiety

The question I hear most often in clinic about CBG and CBN is not really a comparison question — it is a confusion question. Both compounds are sold as “anxiety support.” Both are non-intoxicating. Both come from hemp. From the outside, the distinction looks cosmetic. From the inside — from a practitioner’s perspective on how these compounds actually engage the nervous system — they occupy completely different functional roles. CBG is a daytime tool. CBN is a nighttime tool. Once you understand the underlying mechanism, the right choice for your particular presentation becomes a clinical question with a clear answer.

The cannabinoid landscape has expanded substantially over the last decade. Beyond the headline-grabbing THC and CBD, the minor cannabinoids — CBG, CBN, CBC, CBDV, and others — have become some of the most clinically interesting compounds in the modern apothecary. CBG and CBN are two of the most useful of those minor cannabinoids, and they sit at opposite ends of the day-to-night arc. Understanding what each one does, and why, is the foundation for choosing between them.

Cannabigerol (CBG) is the decarboxylated form of cannabigerolic acid (CBGA), and CBGA is the precursor compound from which the major cannabinoids in the plant — THC, CBD, and CBC among them — are biosynthesized. This is why CBG is sometimes called the “mother cannabinoid”: the plant produces CBGA first, then enzymes convert most of it into the more familiar cannabinoids as the plant matures. By the time a fresh hemp flower is harvested, only about 1% of the total cannabinoid content remains as CBG.

Strains bred specifically for higher CBG content typically have lower THC and CBD content as a result — the precursor was conserved instead of converted. Modern CBG products often come from these specially bred chemovars, or from hemp harvested earlier in the growth cycle when CBG levels are higher.

Research on CBG’s pharmacology is still developing, but the receptor profile is increasingly well-described. CBG appears to be a weak partial agonist at the CB1 and CB2 receptors in vitro. Its interaction with CB1 resembles CBD’s more than THC’s, which is why CBG does not produce psychoactive effects despite touching the same receptor system. What sets CBG apart from other cannabinoids is its affinity for adrenergic and serotonin receptors — particularly the 5-HT1A pathway. This is the pharmacological foundation for CBG’s anxiolytic effects.

CBG is biosynthesized in the cannabis plant from cannabigerolic acid (CBGA), the precursor compound that gives rise to most other cannabinoids. CBGA decarboxylates into CBG, and then plant enzymes convert most of the CBG into THC, CBD, and CBC as the flower matures. The leftover CBG is what gets extracted and used in modern hemp products.

It is worth noting that CBG has been identified outside the cannabis plant as well. Helichrysum umbraculigerum, a flowering plant native to southern Africa, has been identified as a richer source of CBG than most cannabis strains. For practical purposes, hemp remains the primary commercial source — but the existence of non-cannabis sources opens interesting possibilities for the future of cannabinoid agriculture.

Because CBG interacts with CB1 receptors in a way similar to CBD, researchers studying its pharmacological profile have proposed analgesic and anti-inflammatory applications. The mechanism — combined with CBG’s lack of psychoactive effect — makes it a candidate for clinical drug development in directions cannabis-derived compounds have not previously been explored.

CBG also appears to have meaningful effects on intraocular pressure, which is the central concern in glaucoma management, and a growing body of preliminary research suggests potential applications in oncology. A 2006 study on plant cannabinoids’ antitumor activity demonstrated meaningful effects on mouse skin melanoma cells in vitro. Among cannabinoids studied for cardiovascular applications, CBG also exhibits a notable ability to prevent platelet aggregation — a property with potential implications for cardiovascular disease prevention.

A 2011 experiment on cannabinoid interactions identified another important property: CBG can reduce nausea, and its opposing effects with CBD at the 5HT1A receptor explain some of the complex interactions between these compounds.

The therapeutic potential is real, but the human clinical evidence remains thinner than the in vitro and animal-model evidence. Most of the clinical claims about CBG are extrapolations from these earlier-phase studies; rigorous human trials are still in early stages.

CBG’s pharmacological profile points toward several distinct clinical applications. The areas with the strongest preliminary support:

Pain Relief

CBG’s weak affinity for the CB1 receptor — combined with its CB2 activity and broader receptor profile — gives it analgesic potential that may exceed CBD or THC in certain contexts. This is one of the more active areas of preliminary research.

Anxiety

This is the use case most readers of this article have come to understand. CBG’s antagonist interaction with the 5HT1A receptor is structurally different from CBD’s agonist activity at the same receptor, but produces a similar anxiolytic outcome through different signaling. Researchers studying cannabinoid effects on anxiety have noted that CBG may contribute meaningfully to the broader anti-anxiety profile of cannabis, particularly through its serotonergic activity.

It is widely accepted in the cannabinoid literature that cannabinoids can affect mood and emotion. THC is the most commonly recognized example. CBG operates differently — non-intoxicating, daytime-appropriate — but accesses some of the same emotional regulation pathways.

Reducing Intraocular Pressure

Smoking cannabis has been shown to lower intraocular pressure, an effect that has been replicated specifically with CBN and CBG. Comparative experiments have shown both minor cannabinoids producing moderate effects on IOP at lower doses, without the side effects (hyperemia, conjunctival erythema) that limit THC’s clinical use in this application.

CBG also lacks the neurotoxicity and ocular toxicity associated with THC and CBN at higher doses. For glaucoma research specifically, this makes CBG a candidate for combination therapy with agents that enhance aqueous outflow.

Neuroprotective Properties

CBG’s non-psychoactivity combined with its receptor profile makes it especially interesting for diseases of the central nervous system. Comparative studies of CBD and CBG in animal models of neurotoxicity and oxidative stress have demonstrated that both compounds exert antioxidant activity in cells lining the CNS, with restoration of cortical serotonin content.

Human cell research has shown CBG reducing the proliferation of pro-inflammatory proteins and DNA damage markers in astrocytes. Preliminary work in animal models of Huntington’s disease has shown CBG aiding recovery on multiple measures — motor function, striatal neuron preservation, microgliosis attenuation, and inflammatory marker reduction.

A synthetic CBG analog, VCE-003, has been investigated in models of multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis with varied but consistently neuroprotective results.

Antibacterial Activity

Like the other major cannabinoids (THC, CBC, CBD, CBN), CBG has demonstrated potent antibacterial activity against methicillin-resistant Staphylococcus aureus and related drug-resistant strains. Additional research on activity against Streptococcus mutans and prevention of bacterial biofilm formation suggests applications across both dental and clinical infection control contexts.

Reduction of Inflammation

A 2021 study on CBG derivatives showed that three synthetic analogs (HUM-223, HUM-233, HUM-234) display analgesic and anti-inflammatory properties, with HUM-234 also showing potential for metabolic regulation in high-fat-diet mouse models.

Appetite Stimulation

The “munchies” effect has traditionally been attributed to THC, but CBG appears to function as an appetite stimulant as well. Two separate animal studies (first, second) showed CBG doses of 30 and 240 mg/kg increasing feeding behavior without affecting motor activity. This opens potential applications in oncology, where CBG may reduce anorexia, metabolic dysfunction, and weight loss associated with cytotoxic chemotherapy agents like cisplatin.

CBN — cannabinol — is a cannabinoid derivative of THC. It forms when THC undergoes oxidation through exposure to heat, light, and air, which is why aged cannabis tests higher for CBN than fresh samples. In a freshly harvested hemp flower, CBN content is minimal; the cannabinoid emerges as the THC degrades over time.

Despite the structural relationship with THC, CBN has its own pharmacological profile. Like THC, it shows partial affinity for the CB1 and CB2 receptors, though substantially weaker than THC’s. It also exhibits activity at TRP ion channels and inhibits the reuptake of monoamine transmitters — norepinephrine, dopamine, and serotonin — which extends its mechanism beyond direct cannabinoid receptor binding.

CBN holds a historical distinction in the field: it was the first cannabinoid isolated and identified from cannabis. This was almost certainly a function of the poor storage conditions of early cannabis transportation — by the time samples reached the laboratories that would analyze them, much of the original THC had oxidized into CBN.

Because CBN is derived from THC, it retains a partial psychoactive profile. Comparative pharmacology research estimates its potency at roughly 25% of THC’s — which is enough to produce mild receptor effects but far below the threshold of perceived intoxication at functional sleep doses.

Like most cannabinoids, CBN originates from cannabis, but unlike CBG it is not synthesized directly by the plant. It is the result of an oxidation process that converts THC into CBN over time, which is why natural CBN concentrations in fresh cannabis are very low.

Modern manufacturers do not wait for natural oxidation — they synthesize CBN through controlled processes like Soxhlet extraction or THC aromatization. The latter is currently the most cost-effective approach to producing the cannabinoid at scale, though it raises sourcing questions about the underlying THC supply that hemp-derived CBN does not face.

CBN’s chemical stability is among the highest in the cannabinoid family. Plant material dating back to 750 BCE was found in a tomb containing remarkably high CBN levels — a striking demonstration of the cannabinoid’s resilience over thousands of years.

Understanding CBN’s therapeutic potential starts with its receptor pharmacology. Although it derives from THC, CBN shows weak affinity for the CB1 receptor and preferentially binds CB2 — predominantly expressed in the immune system. This receptor preference explains why CBN has limited effect on the central nervous system relative to THC, while opening distinct therapeutic possibilities through CB2 engagement.

Analgesic and Anti-Inflammatory Properties

CBN’s analgesic and anti-inflammatory profile makes it valuable in pain management contexts. Research on CBN’s pain-modulation effects has shown it can mitigate various pain disorders by reducing mechanical sensitivity, particularly when co-administered with CBD.

Additional experiments have shown CBN suppressing pro-inflammatory cytokines (interleukins 2 through 13) and preventing mucus production — a profile that suggests potential applications in respiratory allergy management.

Antibacterial Properties

CBN shares the broader cannabinoid family’s activity against drug-resistant bacterial strains. Research on cannabinoid antibacterial activity has characterized CBN as “highly effective” against antibiotic-resistant pathogens like methicillin-resistant Staphylococcus aureus.

Appetite Stimulation

Like CBG, CBN demonstrates the ability to stimulate appetite. In animal model studies, CBN has been shown to increase food consumption and feeding time. Because CBN is not a narcotic, this property opens potential clinical applications where appetite stimulation is medically beneficial.

Skin Conditions

An ongoing Phase II clinical trial has shown CBN-based formulations to be effective in treating epidermolysis bullosa — a rare condition involving easy blistering of the mucus membrane and skin. The formulation is well-tolerated on open skin wounds without systemic side effects.

Sleep

CBN’s reputation as the “sleepy cannabinoid in old weed” has dominated public conversation about the compound for decades, often without the underlying mechanism being well-understood. The mechanism is now substantially clearer than it was: CBN acts directly on sleep architecture through partial CB1 receptor agonism, producing measurable polysomnography effects independent of THC.

The 2024 University of Sydney polysomnography study documented CBN’s direct effect on sleep in a controlled animal model, with NREM and REM both increasing — and the NREM effect comparable in magnitude to zolpidem but without the REM suppression hypnotic medications produce. The human evidence has followed: a 2023 placebo-controlled trial from Bonn-Miller and colleagues showed 20mg CBN over seven nights significantly reducing nighttime awakenings and overall sleep disturbance in adults with self-rated poor sleep quality.

Older animal research had already suggested that CBN doses under 5 mg/kg can cause drowsiness, with combination studies showing THC and CBN increasing sedation synergistically. The modern picture: CBN works on sleep architecture in its own right, and combining cannabinoids accentuates the effect through what is now well-described as the “entourage effect.”

In Dragon Hemp’s Sleep Gummies, CBN is paired with premium-grade CBD in a precisely formulated ratio designed to address both the nervous-system layer of sleep failure (CBD) and the architecture layer (CBN). The combination is built around how most chronic sleep disruption actually presents: layered, with both onset and maintenance components.

CBN is closely related to THC chemically, but its receptor profile diverges enough that the felt experience does not match THC’s. It does not produce the psychotomimetic effects characteristic of THC, and at functional sleep doses it does not cross the threshold of perceived intoxication — much like the related minor cannabinoid THCV, which similarly resists categorization as either a sedative or a psychoactive in the traditional sense.

The felt experience of CBN at functional doses is closer to a deep, settled relaxation than to any conventional “high.” The architecture effects on sleep depth and continuity are real and measurable, but they emerge through receptor activity too mild to cross into intoxication.

The fundamental difference between CBG and CBN is structural and developmental. CBG is what remains when cannabigerolic acid converts to other cannabinoids — THC, CBD, CBC, and others. It is upstream in the cannabinoid biosynthesis pathway. CBN, by contrast, is downstream — it is what THC becomes when exposed to light and air over time.

Mechanistically, they engage different receptor systems and produce different felt effects. CBG modulates daytime nervous-system regulation through CB1/CB2 and serotonergic pathways. CBN stabilizes sleep architecture through partial CB1 agonism. Neither is “stronger” than the other — they operate in different functional categories.

For the practitioner pivot — the question of how to actually use these compounds in clinical practice — the cleanest framing is temporal. CBG belongs to the day. CBN belongs to the night.

This is the central question this article was written to answer, and the answer is more nuanced than a simple comparison can capture. Both compounds engage the nervous system in ways that can reduce anxiety, but they do so at different times of day and through different mechanisms.

Use CBG when the anxiety is happening during the day and you need to remain functional. CBG’s serotonergic activity and partial CB1/CB2 agonism produce a steadying effect without sedation. People who need to drive, work, parent, or otherwise operate in the world while addressing anxiety usually do better with CBG than with CBN — because CBG calms without sedating, and CBN, even at functional doses, produces enough architecture activity to make daytime use unwise.

Use CBN when the anxiety is interfering with sleep — either preventing sleep onset (through nighttime rumination, the racing mind that does not turn off when the lights do), or fragmenting the second half of the night through 2–3 AM wake-ups. CBN’s direct effect on sleep architecture matches this presentation cleanly. The Bonn-Miller trial dosed CBN at 20mg nightly and found significant reductions in nighttime awakenings and sleep disturbance — exactly the symptom pattern that defines anxiety-driven sleep maintenance failure.

Use both — usually with CBD as the foundation — when the anxiety is layered: persistent through the day AND disrupting sleep at night. The combination protocol I recommend in clinic for this presentation is CBD daily as the baseline, with CBG added in the morning for daytime regulation and CBN added at night for sleep architecture. The result is a protocol that addresses the full arc — daytime arousal, evening wind-down, nighttime maintenance — rather than just a single failure point.

The “entourage effect” — the idea that cannabinoids work better in combination than in isolation — applies strongly here. Different cannabinoids, working through different pathways, can together address what a single compound cannot. This is why most of Dragon Hemp’s formulations combine cannabinoids rather than relying on isolates. For a deeper read on the foundational CBD layer underneath this protocol, see our companion article on CBN vs CBD. For the sleep-specific application, see our companion article on CBD or CBN for sleep.

Yes — they address different layers of the problem and do not interact unfavorably. The standard protocol is CBG during the day and CBN at night, with CBD as the foundational compound underneath both.

If you have ever consumed a full-spectrum hemp product, you have likely taken these two together already. Modern formulations simply concentrate the cannabinoids that matter most for the specific clinical outcome being targeted, rather than relying on the trace amounts naturally present in raw plant material.

The hemp market remains uneven. The 2018 Farm Bill opened federal access to hemp-derived products, but federal access did not impose federal quality control. Independent testing has found that roughly a quarter of CBD products on the market fail to meet basic purity standards. Comparable patterns hold for CBG and CBN, often more severely — because the cannabinoids are more expensive to produce, the temptation to underdose products is correspondingly stronger.

The standard I would hold any minor-cannabinoid product to before recommending it: a verified dose in the functional range (10mg or higher for CBG, 10–25mg for CBN), a current third-party Certificate of Analysis showing the full cannabinoid panel, contaminant testing for heavy metals, pesticides, and residual solvents, and a clear sourcing chain that confirms hemp-derived rather than THC-conversion origin.

The Dragon Hemp formulations were built to this standard — organic cannabinoids, vegan and low-sugar, formulation logic driven by clinical effect rather than cost engineering — which is why the recommendations below default to those products rather than to broader market alternatives. The same criteria apply to any product you are considering. For daytime nervous-system support, Calming Gummies center full-spectrum CBD, while the Leisure Gummies are the Dragon Hemp formulation that contains CBG — paired with CBD, CBC, and a low THC dose — though Leisure is positioned for social uplift rather than anxiety per se. For nighttime sleep architecture support, Sleep Gummies combine CBD and CBN; Sleep Gummies+ add a 2.5mg THC microdose for layered architecture support when the standard combination is not enough. For the deeper root-cause TCM herbal layer, Sleep Tincture integrates the classical Suan Zao Ren Tang formula with nano-emulsified cannabinoids.

What I see most often in clinic is not someone in need of CBG, or someone in need of CBN. It is someone whose nervous system has been running on cortisol for too long — daytime anxiety that compresses into nighttime sleep failure, sleep failure that compounds the daytime anxiety, the whole arc unwinding in a loop. Choosing between CBG and CBN, in that context, is the wrong frame. The right frame is which point in the arc are you trying to intervene at — and once you have answered that, the cannabinoid choice follows. CBG for the daytime layer. CBN for the nighttime layer. CBD underneath both as the foundation. And, when the disruption is chronic enough to reach beyond what cannabinoids alone can address, the TCM herbal layer that has been the deeper restorative work of Chinese medicine for centuries. The compounds are tools. The protocol is the practice.

Practitioner-Founded.
Rooted in Clinical Expertise.

Dragon Hemp was established by Kevin Menard, LAc, a specialist in Sports Medicine Acupuncture and Traditional Chinese Medicine. Developed in his Sag Harbor clinic, our formulations bridge the gap between ancient herbal wisdom and modern cannabinoid research to address the root causes of pain, sleep, and wellness issues.

From our Rest & Restoration and Essential Wellbeing collections to our targeted Aches & Pains topicals, every product is formulated with organically grown botanicals and premium hemp extracts. We invite you to experience our sophisticated fusion of tradition and innovation at our flagship apothecary at 108 Main Street, Sag Harbor, or explore our full range of tinctures, gummies, and balms online.

• Learn more about our botanicals in our Ingredients Index.
  
  
• Discover the design and ethos of our Sag Harbor apothecary in Forbes.